Background: Myasthenia gravis (MG) is a neuromuscular junction disorder usually associated with a thymic lesion. Aims and objective: To study the clinical, serological, and thymic pathology in patient of MG from this corner of the country. Material and method: A retrospective study involving all myasthenia patients presenting to neurology and cardio-thoracic department from the year 2013 to 2020. The clinical findings, Osserman grade of severity, antibodies profile, computed scanning thorax findings and histopathology of the thymic lesion were noted and collected as data. Results: Thirty patients of MG were included with mean age of onset being 39.10 ± 15.77 years which included 22 females and eight males. Four patients had only ocular findings while 26 patients had generalized myasthenia with three patients of respiratory failure. Ach receptor antibodies were positive in 27 patients and negative in two patients. Anti-MUSK was positive in one out of five patients. Abnormal findings in CT thorax seen in 20 patients which included enlarged thymic gland in 11 patients, thymic hyperplasia in two patients, thymoma in four patients, and anterior mediastinal mass in three patients. Thymectomy was done in eighteen patients with thymoma as the most common histopathological findings seen in eight patients, follicular hyperplasia in five patients; other was thymic hyperplasia, thymic cyst, normal thymus gland, and features of sarcoidosis in one patient. Conclusion: MG is a treatable autoimmune disorder with a variety of clinical, radiological, and histopathological findings.

Baiakmenlang Synmon has completed her neurology from GMCH and has been practicing neurology for the last ten years. At present holding the post associate professor at NEIGRIHMS, India with a keen interest to impart knowledge to the upcoming generation. Her area of interest is epilepsy, CNS infections and autoimmune disorders. She has around 25 publications in both regional and national journal with 49 citations till date. Her upcoming project is on stroke registry, treatment gap in epilepsy and the IN SHORT trial in tuberculosis.